Myriad Genetics (MYGN) Competitors

$3.62 -0.11 (-2.95%)

Closing price 04:00 PM Eastern

Extended Trading

$3.69 +0.07 (+1.82%)

As of 05:17 PM Eastern

MYGN vs. ZBIO, MNKD, GERN, LXRX, and OPK

Should you buy Myriad Genetics stock or one of its competitors? MarketBeat compares Myriad Genetics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Myriad Genetics include Zenas BioPharma (ZBIO), MannKind (MNKD), Geron (GERN), Lexicon Pharmaceuticals (LXRX), and OPKO Health (OPK). These companies are all part of the "biotechnology" industry.

How does Myriad Genetics compare to Zenas BioPharma?

Myriad Genetics (NASDAQ:MYGN) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

Zenas BioPharma has a net margin of 0.00% compared to Myriad Genetics' net margin of -48.24%. Myriad Genetics' return on equity of -8.51% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-48.24%	-8.51%	-4.48%
Zenas BioPharma	N/A	-85.64%	-61.86%

In the previous week, Myriad Genetics had 1 more articles in the media than Zenas BioPharma. MarketBeat recorded 7 mentions for Myriad Genetics and 6 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 1.05 beat Myriad Genetics' score of 0.36 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Myriad Genetics	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zenas BioPharma	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Myriad Genetics presently has a consensus target price of $6.40, suggesting a potential upside of 76.80%. Zenas BioPharma has a consensus target price of $44.29, suggesting a potential upside of 134.32%. Given Zenas BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe Zenas BioPharma is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Zenas BioPharma	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44

Myriad Genetics has a beta of 1.81, meaning that its stock price is 81% more volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.61, meaning that its stock price is 161% less volatile than the broader market.

Myriad Genetics has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$824.50M	0.41	-$365.90M	-$4.30	N/A
Zenas BioPharma	$10M	108.43	-$377.74M	-$7.81	N/A

99.0% of Myriad Genetics shares are owned by institutional investors. 1.9% of Myriad Genetics shares are owned by company insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Myriad Genetics beats Zenas BioPharma on 9 of the 16 factors compared between the two stocks.

How does Myriad Genetics compare to MannKind?

Myriad Genetics (NASDAQ:MYGN) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

MannKind has a net margin of -6.63% compared to Myriad Genetics' net margin of -48.24%. Myriad Genetics' return on equity of -8.51% beat MannKind's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-48.24%	-8.51%	-4.48%
MannKind	-6.63%	-11.21%	-3.92%

In the previous week, MannKind had 4 more articles in the media than Myriad Genetics. MarketBeat recorded 11 mentions for MannKind and 7 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 0.36 beat MannKind's score of 0.29 indicating that Myriad Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Myriad Genetics	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MannKind	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Myriad Genetics presently has a consensus target price of $6.40, suggesting a potential upside of 76.80%. MannKind has a consensus target price of $8.84, suggesting a potential upside of 174.65%. Given MannKind's stronger consensus rating and higher possible upside, analysts clearly believe MannKind is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Myriad Genetics has a beta of 1.81, meaning that its stock price is 81% more volatile than the broader market. Comparatively, MannKind has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market.

MannKind has lower revenue, but higher earnings than Myriad Genetics. MannKind is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$824.50M	0.41	-$365.90M	-$4.30	N/A
MannKind	$360.78M	2.76	$5.86M	-$0.07	N/A

99.0% of Myriad Genetics shares are owned by institutional investors. Comparatively, 49.5% of MannKind shares are owned by institutional investors. 1.9% of Myriad Genetics shares are owned by company insiders. Comparatively, 2.6% of MannKind shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

MannKind beats Myriad Genetics on 10 of the 16 factors compared between the two stocks.

How does Myriad Genetics compare to Geron?

Geron (NASDAQ:GERN) and Myriad Genetics (NASDAQ:MYGN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

In the previous week, Geron had 9 more articles in the media than Myriad Genetics. MarketBeat recorded 16 mentions for Geron and 7 mentions for Myriad Genetics. Geron's average media sentiment score of 0.75 beat Myriad Genetics' score of 0.36 indicating that Geron is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Geron	3 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Myriad Genetics	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

73.7% of Geron shares are held by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are held by institutional investors. 1.7% of Geron shares are held by insiders. Comparatively, 1.9% of Myriad Genetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Geron has higher earnings, but lower revenue than Myriad Genetics. Geron is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$183.88M	4.88	-$83.50M	-$0.11	N/A
Myriad Genetics	$824.50M	0.41	-$365.90M	-$4.30	N/A

Geron currently has a consensus target price of $2.50, suggesting a potential upside of 78.57%. Myriad Genetics has a consensus target price of $6.40, suggesting a potential upside of 76.80%. Given Geron's higher possible upside, equities research analysts clearly believe Geron is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Myriad Genetics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Geron has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, Myriad Genetics has a beta of 1.81, meaning that its stock price is 81% more volatile than the broader market.

Geron has a net margin of -35.48% compared to Myriad Genetics' net margin of -48.24%. Myriad Genetics' return on equity of -8.51% beat Geron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-35.48%	-23.31%	-10.08%
Myriad Genetics	-48.24%	-8.51%	-4.48%

Summary

Geron beats Myriad Genetics on 8 of the 15 factors compared between the two stocks.

How does Myriad Genetics compare to Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Myriad Genetics (NASDAQ:MYGN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

In the previous week, Lexicon Pharmaceuticals had 13 more articles in the media than Myriad Genetics. MarketBeat recorded 20 mentions for Lexicon Pharmaceuticals and 7 mentions for Myriad Genetics. Lexicon Pharmaceuticals' average media sentiment score of 0.63 beat Myriad Genetics' score of 0.36 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexicon Pharmaceuticals	2 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Myriad Genetics	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are held by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are held by insiders. Comparatively, 1.9% of Myriad Genetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Lexicon Pharmaceuticals has higher earnings, but lower revenue than Myriad Genetics. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80M	20.78	-$50.34M	-$0.07	N/A
Myriad Genetics	$824.50M	0.41	-$365.90M	-$4.30	N/A

Lexicon Pharmaceuticals currently has a consensus target price of $4.55, suggesting a potential upside of 95.28%. Myriad Genetics has a consensus target price of $6.40, suggesting a potential upside of 76.80%. Given Lexicon Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Lexicon Pharmaceuticals is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Myriad Genetics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Lexicon Pharmaceuticals has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Myriad Genetics has a beta of 1.81, meaning that its stock price is 81% more volatile than the broader market.

Lexicon Pharmaceuticals has a net margin of -37.46% compared to Myriad Genetics' net margin of -48.24%. Myriad Genetics' return on equity of -8.51% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%
Myriad Genetics	-48.24%	-8.51%	-4.48%

Summary

Lexicon Pharmaceuticals beats Myriad Genetics on 10 of the 16 factors compared between the two stocks.

How does Myriad Genetics compare to OPKO Health?

OPKO Health (NASDAQ:OPK) and Myriad Genetics (NASDAQ:MYGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

OPKO Health currently has a consensus target price of $1.55, suggesting a potential upside of 40.91%. Myriad Genetics has a consensus target price of $6.40, suggesting a potential upside of 76.80%. Given Myriad Genetics' higher probable upside, analysts plainly believe Myriad Genetics is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17
Myriad Genetics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

64.6% of OPKO Health shares are held by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are held by institutional investors. 49.7% of OPKO Health shares are held by insiders. Comparatively, 1.9% of Myriad Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, OPKO Health and OPKO Health both had 7 articles in the media. OPKO Health's average media sentiment score of 0.61 beat Myriad Genetics' score of 0.36 indicating that OPKO Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OPKO Health	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Myriad Genetics	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

OPKO Health has a net margin of -36.63% compared to Myriad Genetics' net margin of -48.24%. Myriad Genetics' return on equity of -8.51% beat OPKO Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OPKO Health	-36.63%	-16.78%	-10.98%
Myriad Genetics	-48.24%	-8.51%	-4.48%

OPKO Health has higher earnings, but lower revenue than Myriad Genetics. OPKO Health is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OPKO Health	$581.12M	1.43	-$225.68M	-$0.27	N/A
Myriad Genetics	$824.50M	0.41	-$365.90M	-$4.30	N/A

OPKO Health has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market. Comparatively, Myriad Genetics has a beta of 1.81, meaning that its share price is 81% more volatile than the broader market.

Summary

OPKO Health and Myriad Genetics tied by winning 8 of the 16 factors compared between the two stocks.

Get Myriad Genetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MYGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MYGN vs. The Competition

Export

Metric	Myriad Genetics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$341.91M	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-0.84	18.81	20.87	25.58
Price / Sales	0.41	181.67	521.63	63.56
Price / Cash	1.08	122.51	42.94	55.34
Price / Book	1.01	6.74	9.86	6.70
Net Income	-$365.90M	$24.11M	$3.55B	$333.77M
7 Day Performance	-11.49%	0.07%	-0.32%	0.45%
1 Month Performance	-26.27%	0.84%	1.34%	4.06%
1 Year Performance	-5.73%	78.10%	41.03%	36.21%

Myriad Genetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MYGN Myriad Genetics	3.8096 of 5 stars	$3.62 -2.9%	$6.40 +76.8%	-9.2%	$341.91M	$824.50M	N/A	2,700
ZBIO Zenas BioPharma	3.3688 of 5 stars	$20.40 +3.9%	$44.14 +116.4%	+119.3%	$1.13B	$10M	N/A	N/A	News Coverage Earnings Report Analyst Forecast
MNKD MannKind	3.7163 of 5 stars	$3.36 -4.5%	$8.84 +163.2%	-32.0%	$1.09B	$348.97M	N/A	400
GERN Geron	2.7951 of 5 stars	$1.39 flat	$2.50 +79.9%	+17.5%	$891.71M	$183.88M	N/A	70	High Trading Volume
LXRX Lexicon Pharmaceuticals	2.616 of 5 stars	$2.31 +15.5%	$4.55 +97.0%	+287.3%	$888.39M	$49.80M	N/A	140	Earnings Report Analyst Forecast Analyst Revision High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MYGN) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Myriad Genetics (MYGN) Competitors

MYGN vs. ZBIO, MNKD, GERN, LXRX, and OPK

How does Myriad Genetics compare to Zenas BioPharma?

Summary

How does Myriad Genetics compare to MannKind?

Summary

How does Myriad Genetics compare to Geron?

Summary

How does Myriad Genetics compare to Lexicon Pharmaceuticals?

Summary

How does Myriad Genetics compare to OPKO Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYGN vs. The Competition

Myriad Genetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Myriad Genetics (MYGN) Competitors

MYGN vs. ZBIO, MNKD, GERN, LXRX, and OPK

How does Myriad Genetics compare to Zenas BioPharma?

Is MYGN or ZBIO more profitable?

Does the media refer more to MYGN or ZBIO?

Do analysts rate MYGN or ZBIO?

Which has more risk and volatility, MYGN or ZBIO?

Which has preferable valuation & earnings, MYGN or ZBIO?

Do insiders & institutionals hold more shares of MYGN or ZBIO?

Summary

How does Myriad Genetics compare to MannKind?

Is MYGN or MNKD more profitable?

Does the media refer more to MYGN or MNKD?

Do analysts rate MYGN or MNKD?

Which has more risk and volatility, MYGN or MNKD?

Which has preferable valuation & earnings, MYGN or MNKD?

Do insiders & institutionals hold more shares of MYGN or MNKD?

Summary

How does Myriad Genetics compare to Geron?

Does the media favor GERN or MYGN?

Do institutionals & insiders hold more shares of GERN or MYGN?

Which has higher valuation & earnings, GERN or MYGN?

Do analysts prefer GERN or MYGN?

Which has more volatility and risk, GERN or MYGN?

Is GERN or MYGN more profitable?

Summary

How does Myriad Genetics compare to Lexicon Pharmaceuticals?

Does the media favor LXRX or MYGN?

Do institutionals & insiders hold more shares of LXRX or MYGN?

Which has higher valuation & earnings, LXRX or MYGN?

Do analysts prefer LXRX or MYGN?

Which has more volatility and risk, LXRX or MYGN?

Is LXRX or MYGN more profitable?

Summary

How does Myriad Genetics compare to OPKO Health?

Do analysts prefer OPK or MYGN?

Do insiders and institutionals believe in OPK or MYGN?

Does the media favor OPK or MYGN?

Is OPK or MYGN more profitable?

Which has stronger earnings & valuation, OPK or MYGN?

Which has more risk and volatility, OPK or MYGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYGN vs. The Competition

Myriad Genetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools